Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Dendreon: The Best Revenge
- Derek Lowe submits: Dendreon DNDN is a company that's really been through it, as have their investors. Many will remember the upheaval back in 2007, when the company showed what they felt were impressive results for their autologous prostate cancer immunotherapy Provenge, got a favorable reception from the FDA's...
- External links 2009-04-14
- Lilly's Alzheimer Drug Lawsuits Just Got Messier
- Derek Lowe submits: Well, this doesn't look good for Lilly LLY. A huge pile of court documents has been unsealed in the ongoing lawsuits about Zyprexa's off-label promotion. The company has already paid some serious fines, and is now fighting it out with insurance companies and other plaintiffs who...
- External links 2009-06-15
- A View from Pfizer's Corner Offices
- Derek Lowe submits: There's a good article from Lee Howard up at The Day (the New London/Groton newspaper) on the changes going on at Pfizer. It's the story according to management, though, which is worth having for its compare-and-contrast uses: Despite the looming uncertainty, according to company...
- External links 2009-06-18
- Ariad Pharma: Professors Patent Pathways and Possibly Profit?
- Derek Lowe submits: Nature Biotechnology has a good wrap-up of the Ariad ARIA patent case, and it includes some insights into the whole "patent the pathway and profit" mindset. That was the heart of Ariad's strategy: they licensed a patent on NF-kappaB from Harvard, MIT, and the Whitehead institute,...
- External links 2009-06-18
- The Bug in Genzyme's Side
- Derek Lowe submits: We organic chemists have it easy compared to the cell culture people. After all, our reactions aren't alive. If we cool them down, they slow down, and if we heat them up, they'll often pick up where they left off. They don't grow, they don't get...
- External links 2009-06-22
- Is Medarex's Prostate Cancer Drug a Success? Too Early to Tell
- Derek Lowe submits: What's really going on with Medarex MEDX and ipilimumab? The company made news over the weekend with a press release from the Mayo Clinic, detailing what appears to be a substantial response in two prostate cancer patients. But the more you look at the story, the...
- External links 2009-06-23
- GlaxoSmithKline Thinks It's Turning Things Around
- Derek Lowe submits: There are some interesting statements from GlaxoSmithKline GSK CEO Andrew Witty here at Reuters. He admits that morale was completely in the scupper around the place a few months ago, which certainly seems to be true, but says that they're turning things around. To that point,...
- External links 2009-06-25
- Elsevier Publicists Go Too Far
- Derek Lowe submits: Via a reader comes this article, which takes us to Elsevier's RUK hard-hitting textbook publishing operation. The co-authors of a psychology text for the publisher were recently taken aback to get this e-mail from a publicist at the company: Congratulations and thank you...
- External links 2009-06-25
- Lilly's Free Compound Screening Will Draw Many Takers
- Derek Lowe submits: Not long ago, I wrote about a Pfizer PFE program for smaller companies to come screen their targets against Pfizer's compound bank. Now Eli Lilly LLY has flipped that around. In an initiative to bring other people's compounds out of the stockrooms and off the shelves,...
- External links 2009-06-29
- Merck's Heart Failure Drug Candidate Hits the Skids
- Derek Lowe submits: There is no good way to spin a Phase III failure. By then you've made it past the main reasons for a drug to wipe out PK and total mechanistic failure. A breakdown at this stage is a more subtle affair (well, except for the money...
- External links 2009-06-08
- Glaxo Does a Deuterium Deal
- Derek Lowe submits: Well, there's someone who certainly believes in the deuterated-drug idea! GlaxoSmithKline GSK has announced today that they've signed a deal with Concert Pharmaceuticals to develop these. There's a $35 million payment upfront, which I'm sure will be welcome in this climate, and various milestone and royalty...
- External links 2009-06-02
- Dendreon Investors Learn a Hard Lesson in Stop-Loss Orders
- Derek Lowe submits: We now have more data on Dendreon’s DNDN results for their prostate cancer therapy Provenge, and the numbers do, in fact, look good. This isn't a cure for refractory prostate cancer, but there seems to be a real statistical improvement in survival, with side effects no...
- External links 2009-04-30
- Merck and Elsevier Cross the Line in Joint Medical 'Journal'
- Derek Lowe submits: I've been meaning to write about the latest advance in salesmanship, pioneered by Merck MRK and Elsevier RUK. As most of you will have heard, the two collaborated to produce something called "The Australasian Journal of Bone and Joint Medicine". This appears to have looked like...
- External links 2009-05-11
- Has Goldman Sachs' Drug-Funding Idea Been Shelved Already?
- Derek Lowe submits: Late last year, I wrote about a possible new way to fund drug discovery, a private-equity model that seemed to be in the works at Goldman Sachs GS. The driving force behind the idea seemed to be Jon Symonds, former CFO at AstraZeneca AZN. ...
- External links 2009-05-14
- Arena Pharma Could Be on the Verge of Collapse
- Derek Lowe submits: I wrote in March about locaserin, Arena Pharmaceutical's ARNA serotonin ligand for obesity. Their clinical data had come out, and things at least to me didn't look good. They didn't quite make the minimum threshold for efficacy, and the FDA isn't in a mood to take...
- External links 2009-05-18
- Pfizer's Compound Screen Doesn't Look Like a Great Moneymaker
- Derek Lowe submits: I've heard that Pfizer PFE is doing something unusual with its proprietary compound collection: they're offering to let other people screen it. Now, that's quite a step. Most companies guard their compounds pretty closely, considering them to be key assets. But I'm told...
- External links 2009-05-20
- Isis, Genzyme May Have a Winning Drug
- Derek Lowe submits: Isis Pharmaceuticals ISIS has had a long, tough history developing antisense-based therapeutics. I've lost count of the number of promising candidates they've had (and promising deals they've signed). But the latest one seems to be progressing: mipomersen, designed to block production of the ApoB lipoprotein. ...
- External links 2009-05-21
- Arena's Prospects Will Be in the Eye of the Suitors
- Derek Lowe submits: I’ve been getting a lot of objections to my opinion on Arena’s ARNA obesity candidate lorcaserin. Specifically, the first level of the dispute seems to be whether or not the recent clinical trial results met the FDA’s criteria for efficacy or not. So, let’s look at...
- External links 2009-05-24
- Merck and AstraZeneca: An Uncommon Deal Indeed
- Derek Lowe submits: Well, the ASCO meeting has been roaring along, with dozens of press releases coming out. (Go to Google News and type that acronym in if you want to get the full experience.) They range from the pretty-interesting to the despair-inducing, but one bit of news struck...
- External links 2009-06-02
- Sanofi-Aventis's 'Voluntary' Staff Departures
- Derek Lowe submits: Sanofi Aventis SNY said "no layoffs" in the company's announcement yesterday, but is instead counting on "voluntary staff departures". Here's the press release, courtesy of Fierce Biotech, notable for its relentless insistence on not capitalizing the name of the company. I'm not sure...
- External links 2009-07-01
- << Previous
- page 1 of 5
- Next >>
Refining Tags
- Biotech (65 results)
- Pfizer Inc. (22 results)
- Healthcare (21 results)
- Merck & Co. Inc. (10 results)
- Wyeth (9 results)
- Eli Lilly & Co. (9 results)
- Seeking Alpha (7 results)
- Genentech Inc. (6 results)
- GlaxoSmithKline Plc. (4 results)
- Human Resources (3 results)
- Arena Pharmaceuticals Inc. (3 results)
- AstraZeneca Plc. (3 results)
- ARIAD Pharmaceuticals Inc. (3 results)
- Novartis AG (3 results)
